期刊
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
卷 5, 期 3, 页码 183-188出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsptsci.2c00016
关键词
trace amines; antipsychotics; ulotaront; molecular dynamics; treatment-resistant schizophrenia; depression
Schizophrenia is a complex and severe mental illness. Current treatments primarily target dopamine neurotransmission and have limited effects on negative symptoms and cognitive impairments. Recent research on trace amine associated receptor-1 (TAAR1) suggests it may be a promising nondopaminergic target for treating schizophrenia and related disorders, with fewer side effects.
Schizophrenia is a complex and severe mental illness. Current treatments for schizophrenia typically modulate dopaminergic neurotransmission by D2-receptor blockade. While reducing positive symptoms of schizophrenia, current antipsychotic drugs have little clinical effect on negative symptoms and cognitive impairments. For the last few decades, discovery efforts have sought nondopaminergic compounds with the aim to effectively treat the broad symptoms of schizophrenia. In this viewpoint, we provide an overview on trace amine associated receptor-1 (TAAR1), which presents a clinically validated nondopaminergic target for treating schizophrenia and related disorders, with significantly less overall side-effect burden. TAAR1 agonists may also be specifically beneficial for the substance abuse comorbidity and metabolic syndrome that is often present in patients with schizophrenia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据